Research Article
Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy
Table 2
Changes in soluble checkpoint proteins and plasma cytokines before and after IMRT in NPC.
| | Pre-IMRT radiotherapy | Post-IMRT radiotherapy | Control | p1 | p2 | p3 |
| BTLA | 77.0±59.6 | 76.5±58.9 | 344.1±102.3 | 0.948 | ≤0.001 | ≤0.001 | GITR | 12.1±16.0 | 11.5±15.9 | 13.3±7.4 | 0.709 | 0.022 | 0.009 | HVEM | 4.1±11.6 | 7.7±21.3 | 94.0±18.3 | 0.325 | ≤0.001 | ≤0.001 | IDO | 14.3±16.7 | 14.7±18.5 | 13.9±5.0 | 0.737 | 0.084 | 0.019 | LAG-3 | 121.4±79.5 | 79.7±45.5 | 64.8±28.6 | ≤0.00 | ≤0.001 | 0.087 | sPD-1 | 12.4±7.8 | 30.0±20.6 | 69.7±38.8 | ≤0.001 | ≤0.001 | ≤0.001 | sPD-L1 | 4.7±3.2 | 11.1±3.3 | 13.7±5.6 | ≤0.001 | ≤0.001 | 0.017 | sPD-L2 | 1571.6±719.3 | 1463.3±797.8 | 2901.9±1026.1 | 0.388 | ≤0.001 | ≤0.001 | TIM-3 | 1702.8±867.8 | 2643.3±1243.8 | 2005.6±633.4 | ≤0.001 | 0.087 | 0.005 | CD28 | 58.6±98.6 | 53.2±83.3 | 292.0±76.2 | 0.315 | ≤0.001 | ≤0.001 | CD80 | 99.9±114.4 | 92.6±110.6 | 526.4±454.5 | 0.191 | ≤0.001 | ≤0.001 | CD137 | 8.8±29.4 | 9.6±35.9 | 48.8±38.1 | 0.715 | ≤0.001 | ≤0.001 | CD27 | 358.7±377.0 | 369.9±355.4 | 480.3±368.7 | 0.731 | 0.049 | 0.004 | CD152 | 18.0±20.5 | 17.6±20.6 | 21.7±9.8 | 0.386 | 0.002 | 0.003 | IFN-γ | 65.6±37.4 | 15.2±8.8 | 29.2±16.9 | ≤0.001 | ≤0.001 | ≤0.001 | IL-12p70 | 6.3±0.6 | 3.7±1.2 | 3.5±0.8 | ≤0.001 | ≤0.001 | 0.607 | IL-13 | 14.0±12.3 | 17.7±9.8 | 14.7±8.9 | 0.154 | 0.566 | 0.070 | IL-1β | 6.6±6.7 | 6.1±5.1 | 3.1±5.2 | 0.005 | 0.002 | ≤0.001 | IL-2 | 22.8±23.2 | 19.6±14.0 | 10.2±15.9 | 0.563 | 0.027 | ≤0.001 | IL-4 | 14.2±7.8 | 11.2±5.0 | 16.7±5.7 | 0.782 | 0.119 | ≤0.001 | IL-5 | 13.5±7.9 | 7.2±6.0 | 7.2±3.3 | ≤0.001 | ≤0.001 | 0.036 | IL-6 | 86.2±111.7 | 15.3±11.2 | 9.0±17.6 | ≤0.001 | ≤0.001 | ≤0.001 | TNF-α | 40.8±40.7 | 19.0±8.9 | 9.6±11.8 | ≤0.001 | ≤0.001 | ≤0.001 | GM-CSF | 12.4±15.1 | 13.5±10.9 | 11.1±12.0 | 0.417 | 0.319 | 0.240 | IL-18 | 57.6±79.1 | 49.8±28.0 | 63.4±42.5 | 0.405 | 0.076 | 0.104 | IL-10 | 12.6±19.0 | 3.5±3.6 | 0.8±0.2 | ≤0.001 | ≤0.001 | ≤0.001 | IL-17A | 9.3±9.3 | 1.9±1.5 | 1.6±1.1 | ≤0.001 | ≤0.001 | 0.597 | IL-21 | 6.7±16.4 | 6.3±7.5 | 4.1±5.7 | 0.208 | 0.182 | 0.029 | IL-22 | 153.0±102.6 | 81.6±59.3 | 75.0±20.9 | ≤0.001 | ≤0.001 | 0.171 | IL-23 | 14.3±6.0 | 17.0±18.4 | 15.6±3.4 | 0.904 | 0.127 | 0.024 | IL-27 | 15.1±28.6 | 12.0±11.0 | 23.1±20.1 | 0.517 | ≤0.001 | ≤0.001 | IL-9 | 8.3±7.0 | 5.5±3.9 | 14.8±11.8 | 0.209 | ≤0.001 | ≤0.001 |
|
|
p1, pre-IMRT and post-IMRT. p2, pre-IMRT and control. p3, post-IMRT and control.
|